Literature DB >> 24421680

The use of antiviral drugs for influenza: Guidance for practitioners, 2012/2013; Paediatric summary.

Upton D Allen.   

Abstract

This practice point summarizes the use of antiviral drugs to manage influenza illness in children and youth for the 2012/2013 season. It excerpts a recently published, full-length update of Canadian recommendations for clinicians on the use of antiviral drugs for the prevention and treatment of influenza, with a focus on paediatric antiviral therapy. Detailed information on the selective use of chemoprophylaxis can be found in the source document, which also highlights the importance of secondary bacterial infections (Streptococcus pneumoniae, methicillin-sensitive Staphylococcus aureus and methicillin-resistant S aureus) in cases of severe influenza illness.

Entities:  

Keywords:  Antiviral therapy; Children; Influenza; Neuraminidase inhibitors

Year:  2013        PMID: 24421680      PMCID: PMC3680290     

Source DB:  PubMed          Journal:  Paediatr Child Health        ISSN: 1205-7088            Impact factor:   2.253


  11 in total

1.  Burden of interpandemic influenza in children younger than 5 years: a 25-year prospective study.

Authors:  Kathleen M Neuzil; Yuwei Zhu; Marie R Griffin; Kathryn M Edwards; Juliette M Thompson; Sharon J Tollefson; Peter F Wright
Journal:  J Infect Dis       Date:  2001-12-17       Impact factor: 5.226

2.  Interchangeability of diphtheria, tetanus, acellular pertussis, polio, Haemophilus influenzae type B combination vaccines presently approved for use in Canada for children < 7 years of age.

Authors: 
Journal:  Can Commun Dis Rep       Date:  2005-02-01

3.  Clinical characteristics of paediatric H1N1 admissions in Birmingham, UK.

Authors:  S Hackett; L Hill; J Patel; N Ratnaraja; A Ifeyinwa; M Farooqi; U Nusgen; P Debenham; D Gandhi; N Makwana; E Smit; S Welch
Journal:  Lancet       Date:  2009-08-22       Impact factor: 79.321

4.  Effects of oseltamivir on influenza-related complications in children with chronic medical conditions.

Authors:  Pedro A Piedra; Kathy L Schulman; William A Blumentals
Journal:  Pediatrics       Date:  2009-07       Impact factor: 7.124

5.  Oseltamivir dosing for influenza infection in premature neonates.

Authors:  Edward P Acosta; Penelope Jester; Peter Gal; John Wimmer; Joni Wade; Richard J Whitley; David W Kimberlin
Journal:  J Infect Dis       Date:  2010-08-15       Impact factor: 5.226

6.  Influenza-associated pediatric deaths--United States, September 2010-August 2011.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2011-09-16       Impact factor: 17.586

7.  Neurologic disorders among pediatric deaths associated with the 2009 pandemic influenza.

Authors:  Lenee Blanton; Georgina Peacock; Chad Cox; Michael Jhung; Lyn Finelli; Cynthia Moore
Journal:  Pediatrics       Date:  2012-08-29       Impact factor: 7.124

8.  Oseltamivir and influenza-related complications, hospitalization and healthcare expenditure in healthy adults and children.

Authors:  John G Gums; Elise M Pelletier; William A Blumentals
Journal:  Expert Opin Pharmacother       Date:  2008-02       Impact factor: 3.889

9.  Safety of oseltamivir compared with the adamantanes in children less than 12 months of age.

Authors:  David W Kimberlin; Marwan Shalabi; Mark J Abzug; David Lang; Richard F Jacobs; Gregory Storch; John S Bradley; Kelly C Wade; Octavio Ramilo; José R Romero; Mark Shelton; Charles Leach; Judith Guzman-Cottrill; Joan Robinson; Nazha Abughali; Janet Englund; Jill Griffin; Penny Jester; Gretchen A Cloud; Richard J Whitley
Journal:  Pediatr Infect Dis J       Date:  2010-03       Impact factor: 2.129

10.  Oseltamivir adherence and side effects among children in three London schools affected by influenza A(H1N1)v, May 2009 - an internet-based cross-sectional survey.

Authors:  A Kitching; A Roche; S Balasegaram; R Heathcock; H Maguire
Journal:  Euro Surveill       Date:  2009-07-30
View more
  1 in total

1.  Uncomplicated pneumonia in healthy Canadian children and youth: Practice points for management.

Authors:  Nicole Le Saux; Joan L Robinson
Journal:  Paediatr Child Health       Date:  2015 Nov-Dec       Impact factor: 2.253

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.